Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Bone Marrow Transplantation2011Vol. 47(4), pp. 516–521
Citations Over Time
A I Chen, Robert S. Negrin, A McMillan, J A Shizuru, Linda J. Johnston, Robert Lowsky, David B. Miklos, Sally Arai, W-K Weng, Ginna G. Laport, Keith Stockerl‐Goldstein
Related Papers
- → High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma(2015)22 cited
- → Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma(2018)18 cited
- → Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation(2018)14 cited
- → High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease(1989)62 cited
- → A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)(2002)14 cited